Sun et al. have developed a 12-gene signature, which includes CDH6, that can predict the sensitivity and resistance of glioma patients to targeted molecular therapy, while additionally serving as an independent prognostic factor for glioma patients21. This evidence concerns the gene CDH6 and glioma.